SEATTLE, WA -- (Marketwired) -- 06/02/14 -- Atossa Genetics Inc., (NASDAQ: ATOS) today announced that a presentation will be made at the 2014 American Society of Clinical Oncology (ASCO) Conference at McCormick Place, Chicago, Illinois, involving technology that has been licensed to Atossa by A5 Genetics KFT, Corporation. The Presentation will take place in the General Poster Session of the Breast Cancer Triple-Negative/Cytotoxics/Local Therapy Session on Monday, June 2, from 8:00 AM to 11:45 AM in S Hall A2. The poster presentation is entitled "Application of a dynamic retraining for each patient using case-specific training cohorts to predict survival in breast cancer patients," The work was conducted by Dr. Balázs Győrffy and his collaborators at the Research Laboratory of Pediatrics and Nephrology, Hungarian Academy of Sciences, the Department of Obstetrics and Gynecology, J. W. Goethe-University, the University Medical Center, Hamburg, Germany, Yale Cancer Center Genomics Program, Yale Cancer Center, Yale School of Medicine.
"We are pleased to be a part of this important meeting and present our novel, patent-pending technology. The National Reference Laboratory for Breast Health, Inc., our CLIA-certified subsidiary, is currently validating the dynamic re-discovery algorithm for use in our transcriptome-based gene expression test of breast cancer recurrence. This laboratory developed test, which is currently under development, uses advanced microarray technologies to analyze the entire genetic transcriptome from core needle and excisional biopsies," said Dr. Steven Quay, Chairman, CEO and President of Atossa.
About Atossa Genetics
Atossa Genetics Inc. is focused on improving breast health through the development of laboratory developed tests (LDTs), medical devices and therapeutics. The Company's LDTs are being developed by its subsidiary, The National Reference Laboratory for Breast Health, Inc. The LDTs and the Company's medical devices are being developed so they can be used as companions to therapeutics to treat various breast health conditions. For additional information, please visit www.atossagenetics.com.
Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, including timing of review by the FDA of 510(k) submissions, and actions related thereto, whether Atossa can submit additional information to the FDA in a timely fashion and whether the FDA will find that information acceptable and/or request additional information, the outcome of the FDA re-inspection completed on March 14, 2014, the outcome or timing of regulatory clearances needed by Atossa to sell its products, responses to regulatory matters, Atossa's ability to continue to manufacture and sell its products, recalls of products, the efficacy of Atossa's products and services, performance of distributors, estimated future expenses and cash needs, whether Atossa can launch in the United States and foreign markets the additional tests, devices and therapeutics in its pipeline in a timely and cost effective manner, and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.